Equities

CANbridge Pharmaceuticals Inc

CANbridge Pharmaceuticals Inc

Actions
  • Price (EUR)0.032
  • Today's Change0.003 / 10.34%
  • Shares traded--
  • 1 Year change-79.75%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments137463746
Total Receivables, Net311928
Total Inventory8.789.8213
Prepaid expenses111325
Other current assets, total22----
Total current assets210505812
Property, plant & equipment, net10914530
Goodwill, net------
Intangibles, net764951
Long term investments------
Note receivable - long term------
Other long term assets03.16--
Total assets395702893
LIABILITIES
Accounts payable19810844
Accrued expenses6311569
Notes payable/short-term debt000
Current portion long-term debt/capital leases354039
Other current liabilities, total321635
Total current liabilities328278186
Total long term debt10711513
Total debt14215552
Deferred income tax------
Minority interest------
Other liabilities, total----0
Total liabilities435393199
SHAREHOLDERS EQUITY
Common stock0.030.030.03
Additional paid-in capital3,4633,4623,461
Retained earnings (accumulated deficit)(3676)(3315)(2858)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total17316291
Total equity(40)309693
Total liabilities & shareholders' equity395702893
Total common shares outstanding425424424
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.